September 2011

CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.   Recent Highlights Palatin initiated enrollment in its Phase 2B trial …

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results Read More »

CRANBURY, N.J., Sept. 19, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter, fiscal year 2011 financial results on Thursday, September 22, 2011 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September …

Palatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011 Read More »

CRANBURY, N.J., Sept. 9, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13, 2011, at 12:05 p.m. Eastern Time.  The conference will be held at The Waldorf Astoria in New York, NY. Carl Spana, Ph.D., President …

Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference Read More »